Santiago A. L.
- Country
- Spain
- Department
- Oncology
Research Overview
- A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC)
- Phase I/II Open-Label Study of ALE.C04 and Pembrolizumab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
- Evaluation of Buparlisib and Paclitaxel Versus Paclitaxel Monotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Data & Insights
Has run more than one trial at 33 of 137 partner sites.
Specializations
Head and Neck Cancer Expertise
The investigator specializes in treating advanced forms of head and neck squamous cell carcinoma (HNSCC), with particular focus on both early-stage and metastatic disease management.
- Recurrent and Metastatic HNSCC
- Locoregionally Advanced HNSCC
- Stage III-IVA Resectable Disease
Their work encompasses comprehensive treatment approaches for various stages of head and neck cancer.
Immunotherapy Applications
The investigator focuses on innovative immunotherapeutic approaches, particularly utilizing pembrolizumab and novel antibody treatments in head and neck cancer.
- Monoclonal Antibody Therapy
- Combination Immunotherapy
- PD-L1 Targeted Treatments
Their expertise includes evaluation of novel therapeutic combinations and treatment sequencing strategies.
Treatment Modalities
The investigator works with multiple treatment approaches including neoadjuvant therapy and adjuvant therapy protocols.
- Radiotherapy Integration
- Chemotherapy Combinations
- Multimodal Treatment Strategies
Their work involves optimizing treatment sequences for improved patient outcomes.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.